Abstract 129P
Background
Biliary tract cancers (BTC) are classified as gallbladder tumours (GBC) and intrahepatic (iCCA) or perihilar and distal extrahepatic cholangiocarcinomas (eCCA). BTC’s 3-year recurrence rate is up to 80%. Capecitabine (CAP) is the standard for adjuvant (adj) chemotherapy (CT). We collected a retrospective multicentre Italian series of resected BTC and analysed the impact of adj CT on survival.
Methods
Main variables were ECOG performance status (PS), pre-surgical (SUR) Ca 19.9 value, type of SUR, site, histology, invasion (T), nodal status (N), vascular invasion (V) resection margins (R), grade (G). Median follow-up (FU) was estimated with reverse Kaplan-Meier (KM) approach; median RFS (RFS) and median overall survival (OS) were estimated by KM method.
Results
We included 142 all-stages BTC resected from 2005 to 2022, adj CT was given to 69 BTC. With median FU of 89 months (mo), overall RFS and OS were 17 and 30 mo. Lower ECOG PS was associated with longer RFS and OS (p<0.001). A pre-SUR Ca19.9 ≤ 29 was associated with longer RFS in iCCA (p=0.001) and OS both in iCCA (p=0.010) and GBC (p=0.019). Lower T was associated with longer RFS (p=0.002) and OS (p<0.001) in iCCA and GBC but not in eCCA. N0 status correlated with longer RFS in iCCA (p<0.001) and OS both in iCCA and GBC (p<0.006). R0 status was associated with longer RFS in eCCA (p=0.043) and GBC (p<0.001), showing longer OS only in GBC only (p<0.001). V0 status was associated with longer RFS (p=0.017) and OS (p=0.009) in iCCA . Adj CT didn’t impact both on RFS (p=0.539) and OS (p=0.978) in the whole cohort. After stratification by site, eCCA showed an advantage given by adj CT on mRFS (p=0.047). Comparing all adj CT, CAP performed better in iCCA, with a mRFS of 19 mo. Multivariate Cox regression analysis for RFS and OS was stratified for iCCA, eCCA and GBC: ECOG PS, R and N status retained significant correlation with RFS (p<0.001, p<0.001 and p=0.034, respectively) and OS (p<0.001, p<0.001, p=0.013, respectively). Pre-SUR Ca19.9 value correlated with OS (p=0.001).
Conclusions
In our series, adj CT didn’t impact on survival except for eCCA. Evaluation of multiple prognostic variables (including T, N, R and V status and pre-SUR Ca19.9) is necessary to identify a subgroup of BTC that can benefit more from adj CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17